CARE case report guidelines

# CARE Checklist of information to include when writing a case report

(cc) BY-NC-ND

| Topic | Item No | Checklist item description | Reported on Page Number/Line Number | Reported on Section/Paragraph |
|---|---|---|---|---|
| Title | 1 | The diagnosis or intervention of primary focus followed by the words “case report” | 1, 1 | 1 |
| Key Words | 2 | 2 to 5 key words that identify diagnoses or interventions in this case report, including "case report" | 1,15 | 1 |
| Abstract (no references) | 3a | Introduction: What is unique about this case and what does it add to the scientific literature? | 1,5-12 | 1 |
| | 3b | Main symptoms and/or important clinical findings | 1,5-12 | 1 |
| | 3c | The main diagnoses, therapeutic interventions, and outcomes | 1,5-12 | 1 |
| | 3d | Conclusion—What is the main “take-away” lesson(s) from this case? | 1,5-12 | 1 |
| Introduction | 4 | One or two paragraphs summarizing why this case is unique **(may include references)** | 2,21-33 | 2 |
| Patient Information | 5a | De-identified patient specific information | 2,35-36 | 2 |
| | 5b | Primary concerns and symptoms of the patient | 2,36-38 | 2 |
| | 5c | Medical, family, and psycho-social history including relevant genetic information | 2,37 | 2 |
| | 5d | Relevant past interventions with outcomes | 2,37 | 2 |
| Clinical Findings | 6 | Describe significant physical examination (PE) and important clinical findings | 2,3 ,40-44 | 3 |
| Timeline | 7 | Historical and current information from this episode of care organized as a timeline | 2,38 | 2 |
| Diagnostic Assessment | 8a | Diagnostic testing (such as PE, laboratory testing, imaging, surveys). | 3,45-49 | 4 |
| | 8b | Diagnostic challenges (such as access to testing, financial, or cultural) | 3,45-49 | 4 |
| | 8c | Diagnosis (including other diagnoses considered) | 3,45-49 | 4 |
| | 8d | Prognosis (such as staging in oncology) where applicable | 3,45-49 | 4 |
| Therapeutic Intervention | 9a | Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care) | 3,4 ,60-66 | 6 |
| | 9b | Administration of therapeutic intervention (such as dosage, strength, duration) | 3,4,60-66 | 6 |
| | 9c | Changes in therapeutic intervention (with rationale) | 3,4,60-66 | 6 |

| | | | | |
|---|---|---|---|---|
| Follow-up and Outcomes | 10a | Clinician and patient-assessed outcomes (if available) | 4,66-69 | 6 |
| | 10b | Important follow-up diagnostic and other test results | 4,66-69 | 6 |
| | 10c | Intervention adherence and tolerability (How was this assessed?) | 4,66-69 | 6 |
| | 10d | Adverse and unanticipated events | 4,66-69 | 6 |
| Discussion | 11a | A scientific discussion of the strengths AND limitations associated with this case report | 4,72-99 | 7 |
| | 11b | Discussion of the relevant medical literature **with references** | 4,84-89 | 9 |
| | 11c | The scientific rationale for any conclusions (including assessment of possible causes) | 4,90-94 | 10 |
| | 11d | The primary “take-away” lessons of this case report (without references) in a one paragraph conclusion | 5,101-106 | 12 |
| Patient Perspective | 12 | The patient should share their perspective in one to two paragraphs on the treatment(s) they received | 4,68-69 | 6 |
| Informed Consent | 13 | Did the patient give informed consent? Please provide if requested | **Yes** ☑ | **No** ☐ |

Article information: http://dx.doi.org/10.21037/aot-21-5
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.